Drug-eluting stents for adenosine receptor modulation
View Patent ↗Drug eluting stents (DES) useful for the treatment of restenosis are described. The stents comprise biocompatible polymers and adenosine receptor modulators.
1. A device for implantation into a blood vessel, the device comprising a stent having a coating, where the coating consists of a biocompatible polymer that is poly(lactic-co-glycolic acid)-b-poly(L-lysinse) or polyurethane; 1,3-dipropyl-8-cyclopentyl xanthine (DPCPX); and optionally an adenosine A 2B receptor agonist or an adenosine A 2A receptor agonist,
wherein the DPCPX is released from the stent over a period of from about 7 days to about 100 days and the DPCPX has a surface density in the coating from 0.5 μg/mm 2 to 1 μg/mm 2 .
2. The device of claim 1 wherein the coating consists of poly(lactic-co-glycolic acid)-b-poly(L-lysine) or polyurethane; DPCPX; and an adenosine A 2B receptor agonist.
3. The device of claim 1 wherein the coating consists of poly(lactic-co-glycolic acid)-b-poly(L-lysine) or polyurethane; DPCPX; and an adenosine A 2A receptor agonist.
4. A device for implantation into a blood vessel, the device consisting of a stent coated with a coating consisting of a biocompatible polymer and DPCPX,
wherein the DPCPX is released from the stent over a period of from about 7 days to about 100 days and the biocompatible polymer is selected from the group consisting of poly(lactic-co-glycolic acid)-b-poly(L-lysine), polyurethane, poly(styrene-b-isobutylene-b-styrene), or a combination thereof.
5. A method of treating restenosis in a patient, the method comprising the step of implanting the device of claim 1 into a blood vessel of the patient.
6. The device of claim 1 wherein the DPCPX is present at a ratio of 10 wt % (DPCPX:polymer).
7. The device of claim 1 wherein the DPCPX is present at a ratio of 20 wt % (DPCPX:polymer).
8. The device of claim 1 wherein the DPCPX is present at a ratio of 30 wt % (DPCPX:polymer).
9. The device of claim 1 wherein the surface density is 0.5 μg/mm 2 or 1 μg/mm 2 .
10. The device of claim 1 wherein the surface density is 0.5 μg/mm 2 .
11. The device of claim 1 wherein the coating has a thickness from about 5 μm to about 50 μm.
12. The device of claim 1 wherein the biocompatible polymer is poly(lactic-co-glycolic acid)-b-poly(L-lysine).
13. The device of claim 4 wherein the biocompatible polymer is polyurethane.
14. The device of claim 4 wherein the biocompatible polymer is poly(lactic-co-glycolic acid)-b-poly(L-lysine).
15. The device of claim 4 wherein the DPCPX has a surface density in the coating from 0.5 μg/mm 2 to 1 μg/mm 2 .
16. The device of claim 4 wherein the DPCPX is present at a ratio of 10 wt % (DPCPX:polymer).
17. A device for implantation into a blood vessel, the device consisting of a stent coated with a coating consisting of a biocompatible polymer and DPCPX,
wherein the DPCPX is released from the stent over a period of from about 7 days to about 100 days, the biocompatible polymer is poly(lactic-co-glycolic acid)-b-poly(L-lysine), and the DPCPX has a surface density in the coating from 0.5 μg/mm 2 to 1 μg/mm 2 .
18. The device of claim 17 , wherein the surface density is 0.5 μg/mm 2 or 1 μg/mm 2 , the coating has a thickness from about 5 μm to about 50 μm, the biocompatible polymer is poly(lactic-co-glycolic acid)-b-poly(L-lysine), and the DPCPX is present at a ratio of 10 wt % (DPCPX:polymer).